Clicky

MacroGenics, Inc.(MGNX)

Description: MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.


Keywords: Medicine Biotechnology Cancer Biopharmaceutical Life Sciences Biology Immunology Antibodies Immune System Treatment Of Cancer Autoimmune Disease Monoclonal Antibodies Antibody Monoclonal Antibody Novel Cancer Cambridge Antibody Technology

Home Page: www.macrogenics.com

MGNX Technical Analysis

9704 Medical Center Drive
Rockville, MD 20850
United States
Phone: 301 251 5172


Officers

Name Title
Dr. Scott Koenig M.D., Ph.D. Pres, CEO & Director
Mr. James Karrels Sr. VP, CFO & Corp. Sec.
Mr. Eric Blasius Risser Chief Operating Officer
Dr. Thomas M. Spitznagel Ph.D. Sr. VP of Technical Operations
Dr. Ezio Bonvini Sr. VP of Research & Chief Scientific Officer
Dr. Christopher Shayne James M.D. VP of Investor Relations & Corp. Communications
Mr. Jeffrey Stuart Peters Sr. VP & Gen. Counsel
Dr. Stephen L. Eck M.D., Ph.D. Sr. VP of Clinical Devel. & Chief Medical Officer
Ms. Lynn Cilinski VP, Controller & Treasurer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.1198
Price-to-Sales TTM: 4.079
IPO Date: 2013-10-10
Fiscal Year End: December
Full Time Employees: 427
Back to stocks